The U.S. secured over $1 billion in new manufacturing investment today on the back of President Trump’s push for more domestic production.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Roche Beefs Up
Pharmaceuticals group Roche (RHHBY) said it planned to invest over $700 million in a new drug manufacturing facility in North Carolina. It said it will support its unit Genentech’s future pipeline of next-generation obesity medicines.
Back in March, Roche acquired rights to petrelintide, an obesity therapy from Denmark’s Zealand Pharma. It is currently undergoing mid-stage clinical trials.
Roche’s obesity pipeline also includes experimental obesity and diabetes drugs from its acquisition of Carmot Therapeutics in 2023.
Separately, Roche also announced plans to invest up to $550 million in its diagnostics site in Indianapolis by 2030, to manufacture continuous glucose monitoring systems.
“This initial investment could expand in the future, based on business needs and the U.S. policy environment,” the company said in a statement. Indeed, the move came as the U.S. and China slashed the tariff rates on each other’s country as trade tensions began to ease.
Bud Has Plenty of Bottle
Budweiser-maker Anheuser-Busch InBev (BUD) also brought some cheer to U.S. industry when it said it would invest $300 million in its manufacturing operations in the United States this year.
It also announced the launch of a new plant in Columbus, Ohio. AB InBev had previously said it was boosting investments in key brands such as Budweiser and ramping up efforts to grow at-home consumption, as spending elsewhere – including in bars – remains pressured.
The two companies are the latest in a growing line of companies such as Novartis (NVS), ABB (ABBNY), Honda (HMC) and Apple (AAPL) ramping up U.S. manufacturing. It has come in the wake of President Trump’s tariff policies which partly are aimed at boosting domestic production.
The pharma stocks have also been boosted by the recent Trump executive order to expedite pharmaceutical plant approvals.
The move did little to make the BUD share price merrier with it dropping 1.8%. Roche however was up 1.5% despite President Trump’s move to slash drug prices in the U.S.
Which Stocks Can Benefit from Tariffs?
We have rounded up the stocks likely to benefit from Trump tariffs using our TipRanks comparison tool.
